Moving from Semaglutide to Retatrutide: What the Evidence Shows

Retatrutide's trial results, and why they don't yet change what you can access

Phase 2 data for retatrutide, published in 2023, produced headline figures that spread quickly: participants on the highest dose lost an average of around 17% of body weight over 24 weeks, with some analyses projecting larger reductions over a longer treatment course. Phase 3 trials are underway, and early signals reported by Eli Lilly point toward average weight losses in the range of 20–26% at 48 weeks at the highest doses studied, figures that, if confirmed and regulatory-approved, would place retatrutide at the top of the weight-loss medicine efficacy ladder. The mechanism behind these numbers is the triple agonism: retatrutide activates GLP-1 receptors (which semaglutide also targets), GIP receptors (which tirzepatide adds to GLP-1), and glucagon receptors, which the other licensed medicines do not engage. Adding glucagon receptor activity appears to drive additional energy expenditure on top of the appetite suppression both GLP-1 and GIP pathways provide.

However, phase 3 results published in a peer-reviewed journal and reviewed by a regulatory body are what a medicine needs before it can be prescribed. That process typically takes years from completion of phase 3 trials to licensing decision. Whether retatrutide proves stronger than semaglutide in a properly controlled head-to-head study remains an open question, the efficacy comparisons circulating online are almost all extrapolated from separate trials, not direct evidence.

For anyone currently on semaglutide and wondering whether to wait for retatrutide: the honest answer from the evidence is that waiting is speculative, and the only licensed triple-agonist available in the UK today is tirzepatide (Mounjaro), not retatrutide. A question our prescribers hear regularly is whether patients should pause treatment in anticipation of something new. Pausing an effective treatment without clinical guidance rarely serves patients well.

How semaglutide and retatrutide compare mechanistically, and why that matters for switching

The practical question behind many searches about retatrutide and semaglutide is: if retatrutide becomes available, what would switching actually involve? Understanding the mechanism difference is the starting point. Semaglutide acts on one receptor pathway; retatrutide acts on three. That is not simply a quantitative step up, adding glucagon receptor agonism introduces a different metabolic signal that may affect blood sugar regulation, heart rate and other parameters in ways single and dual agonists do not. A prescriber considering a transition would need to assess those differences against a specific patient's full medical picture.

The titration approach would also differ. Semaglutide (Wegovy) begins at 0.25 mg weekly and steps up across roughly 16 weeks to the maintenance dose. Retatrutide, based on phase 2 protocols, used its own escalation schedule. No UK prescribing guidance exists yet because no UK licence exists yet. What this means practically: a switch is not simply stopping one pen and starting another. Taking retatrutide and semaglutide together is not something any published guidance addresses, and combining agents that share a GLP-1 mechanism is not clinically established practice.

People who are doing well on semaglutide should have that conversation with their prescriber rather than making changes based on pipeline news. You can read more about how semaglutide works as a licensed treatment to understand the evidence base that already exists for your current medicine.

What to do now if you are on Wegovy and curious about retatrutide

The most useful thing anyone on semaglutide can do right now is make the most of the treatment they have access to. Wegovy's STEP 1 trial (which involved nearly 2,000 adults with obesity across 16 countries) reported an average weight reduction of around 15% over 68 weeks alongside lifestyle changes, as published in the New England Journal of Medicine. That is a substantial, well-replicated figure. The higher 7.2 mg dose approved by the MHRA in 2026 narrows the gap with tirzepatide further still. The comparison between semaglutide and retatrutide is one worth keeping an eye on, but watching a pipeline is not a substitute for treatment today.

If your question is more practical (you feel semaglutide has stopped working as well, you want to understand whether tirzepatide might suit you better, or you are simply weighing options before starting anything) those are exactly the kinds of conversations that belong in a clinical consultation rather than a search engine. Some patients also ask whether stacking semaglutide and retatrutide is something their prescriber could consider, and that page sets out what the evidence currently does and does not support. The weight-loss treatment landscape is shifting quickly, and a prescriber who keeps current with the evidence is a better guide than an online forum. Some people time their consultations around payday or before a holiday; either way, the information about what is actually licensed and available in the UK is what should anchor that conversation. You can find an overview of what nume's prescribers assess when reviewing suitability for any licensed GLP-1 treatment on the about us page.

Retatrutide may well earn its licence eventually. When it does, the published SmPC, MHRA approval documentation and NICE appraisal process will define who is eligible and how switching from an existing treatment should be managed. Until then, the NHS guidance on semaglutide as a licensed medicine remains the most relevant clinical reference for anyone currently taking or considering Wegovy in the UK.